FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

٧	vas	hing	ton,	D.C.	20549	

STATEMENT	OF	CHANGES	IN RENEE	ICIAI	OWNERS	SHIP
	O.	CHANCES	II4 DEI4EI	IOIAL	CANIALIK	JI 111

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Zoon Kathryn C						2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]								ionship of Reporting P all applicable) Director		g Person(s) to I		
(Last) (First) (Middle) 400 PROFESSIONAL DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 05/23/2019									Offic belov	er (give title w)	Other below	(specify)	
(Street) GAITHE (City)	GAITHERSBURG MD 20879				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indivi Line) X				
		Tabl	e I - I	Non-Deriv	ative	Sec	uritie	s Ad	cquir	ed, D	isposed o	f, or E	Benefic	ially (Owne	ed		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				.	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities A Disposed Of (d 5) Securit Benefic		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Tra		action(s) 3 and 4)		(111501.4)
Common Stock ⁽¹⁾ 05/23/201					019	9		A	П	5,736(2)	A	\$0	24		24,379	D		
Common Stock 05/28/201				019	.9		S		1,376(3)	D	\$43.38	884(4)	23,003		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	ate Execution Date,		4. Transa Code (8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	e rcisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

- 1. Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan.
- 2. These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company.
- $3. \ The sale \ transactions \ reported \ in \ this \ Form \ 4 \ were \ effected \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan \ adopted \ by \ Dr. \ Zoon.$
- 4. The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$43.04 to \$43.58, inclusive.

/s/ S. Scott Liberman, Attorney-in-fact 05/28/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.